HopeStage
Back to all studies
CompletedNCT02104752

Curcumin Added to Ongoing Treatment for Cognitive Difficulties in Schizophrenia

About this titleRead the official source — NCT02104752

Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Los AngelesSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2014
Recruitment status
Completed
Enrollment listed in the registry
39
Sponsor
VA Greater Los Angeles Healthcare System
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02104752
Official title
Show the full official title

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Los Angeles

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who is behind this study?

The study sponsor is VA Greater Los Angeles Healthcare System.

Did this study involve medication?

Yes. The study involved medication, including Curcumin and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies